Last reviewed · How we verify
NCT05095480
Effect of Red Yeast Rice Beside Statin on Lipid Profile
Phase 4 trial testing Red Yeast Rice Pill in Hyperlipidemias in 92 participants. Completed in 1 April 2021.
1 March 2021
Quick facts
| Lead sponsor | Shiraz University of Medical Sciences |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 92 |
| Start date | 1 March 2019 |
| Primary completion | 1 March 2021 |
| Estimated completion | 1 April 2021 |
| Sites | 1 location across Iran |
Drugs / interventions tested
- Red Yeast Rice Pill — full drug profile →
- Placebo
Conditions studied
- Hyperlipidemias — all drugs for Hyperlipidemias →
Sponsor
Shiraz University of Medical Sciences
Who can join
Adults 55 to 72, any sex, with Hyperlipidemias. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
We conducted a triple-blind clinical trial on 92 patients in 2019. They were randomly divided into a control group of 49 patients and a treatment group of 43 patients. Treatment group received Lesstat and placebo group received the same color tablets
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evaluation the effects of red yeast rice in combination with statin on lipid profile and inflammatory indices; a randomized clinical trial.
Tavan A, Noroozi S, Zamiri B, Gholchin Vafa R, et al · · 2022 · cited 2× · PMID 36434733 · DOI 10.1186/s40795-022-00639-z
Verify or expand the search:
- PubMed search for NCT05095480
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hyperlipidemias
Currently open trials in the same condition.
- NCT06903897 — Social Needs Screening and Chronic Diseases Study (WE CARE) · NA · recruiting
- NCT06049420 — Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients · NA · recruiting
- NCT06461273 — Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome · NA · active not recruiting
- NCT06094491 — Virtual Diabetes Group Visits Across Health Systems · Phase 2 · active not recruiting
- NCT06055036 — Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention · NA · recruiting
Other Shiraz University of Medical Sciences trials
Trials by the same sponsor.
- NCT07254221 — Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients · Phase 4 · not yet recruiting
- NCT06509893 — Ticagrelore Alone Post PCI · Phase 4 · recruiting
- NCT05876819 — Quality of Care and Welfare Services for Disabled Middle Older Adults in Iran Lebanon · enrolling by invitation
- NCT06979427 — CTFFR and Prediction of Non-Significant CAD Lesions · NA · recruiting
- NCT05711004 — Efficacy of Education Via Phone-based Text Messaging (SMS) on Patients With Uncontrolled Hypertension · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05095480 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shiraz University of Medical Sciences
- Last refreshed: 27 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05095480.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing